Spoken Alpha
SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group develops late-stage cancer immunotherapies and small molecule inhibitors. Its lead candidate, galinpepimut-S (GPS), is a peptide vaccine targeting the WT1 protein in blood and solid cancers, currently in a Phase 3 trial for acute myeloid leukemia.
SELLAS Life Sciences Group, Inc is a Healthcare company operating in Biotechnology with a $2.33B market cap.
SLS missed consensus EPS by 0.3% in Q2 FY2026, reported Aug 10, 2026.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add SLS, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for SLS.
$ curl https://api.spokenalpha.com/v1/companies/SLSFAQ
Spoken Alpha indexes SLS's earnings call transcripts at https://spokenalpha.com/companies/SLS. Each call links to attributed speakers and parsed analyst Q&A. SELLAS Life Sciences Group, Inc.'s own investor relations page is at https://ir.sellaslifesciences.com/overview/default.aspx.
SELLAS Life Sciences Group, Inc. (SLS) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-10 | $-0.05 | $-0.04 | -25.0% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-18 | $-0.05 | $-0.07 | +30.4% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-18 | $-0.05 | $-0.06 | +16.7% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.06 | $-0.08 | +25.0% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.07 | $-0.08 | +12.5% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-0.07 | $-0.11 | +36.4% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-25 | $-0.08 | $-0.11 | +25.0% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-12 | $-0.10 | $-0.13 | +23.1% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-0.13 | $-0.17 | +23.5% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-0.21 | $-0.16 | -31.3% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-27 | $-0.25 | $0.09 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.33 | $0.02 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-0.31 | $-0.35 | +11.4% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-0.47 | $-0.29 | -62.1% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-15 | $-0.43 | $-0.32 | -34.4% | $-1.0M | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.34 | $-0.39 | +12.8% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-0.42 | $-0.37 | -13.5% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-0.42 | $-0.42 | 0.0% | $1.0M | — | — | EODHD |
| Q4 FY2021 | 2022-03-30 | $-0.42 | $-0.41 | -2.4% | $-7.6M | — | — | EODHD |
| Q3 FY2021 | 2021-11-11 | $-0.45 | $-0.34 | -32.4% | $0 | — | — | EODHD |
Source: EODHD. SLS reported actuals as published; sparse fields render as —.